首页 > 最新文献

World Journal of Nuclear Medicine最新文献

英文 中文
Status and Development of Nuclear Medicine Over One Decade in Beijing 北京核医学十年的现状与发展
IF 0.6 Pub Date : 2024-04-11 DOI: 10.1055/s-0044-1778712
Fei Luo, J. Geng, Sheng-zu Chen
Objective Our objective was to investigate the basic information of the personnel and facilities of nuclear medicine in Beijing. Methods This survey was performed by the Beijing Quality Control Center in 2018. The investigation included personnel, equipment, and clinical applications, and data were then compared with previous surveys. The paper questionnaires were used for the survey, which required information about the personnel, devices, and clinical applications. Results About 38 nuclear medicine departments in Beijing were involved in the survey. The number of nuclear medicine staff was 531 in 2018, showing an increase of 58.7% over the past decade. Positron emission tomography/computed tomography (PET/CT), single-photon emission computed tomography (SPECT), and single-photon emission computed tomography/computed tomography (SPECT/CT) represented the main nuclear medicine facilities, and the total number of surveyed departments was 18, 24, and 34, respectively. The quality control results showed significant improvement from the 2005 levels. The total number of scintigraphy procedures was estimated at 199,607 (153,185 SPECT and 46,422 PET/CT). The estimated annual number of scintigraphy images was 8.9 per 1,000 population for SPECT and 2.7 per 1,000 population for PET/CT during 2018. The most frequent radioiodine-targeted therapy was 131I-targeted therapy for hyperthyroidism in 2018. Conclusions Nuclear medicine has experienced rapid growth in the past 10 years in Beijing, either in personnel, equipment, and scintigraphy. Future efforts will focus on the use of new isotopes in the diagnosis, implementing quality strategy, and enhancing training.
摘要] 目的 调查北京市核医学人员和设施的基本情况。方法 本次调查由北京市质控中心于 2018 年进行。调查内容包括人员、设备和临床应用,然后将数据与以往的调查进行对比。调查采用纸质问卷,要求填写人员、设备、临床应用等信息。结果 北京约有 38 个核医学科参与了此次调查。2018 年核医学人员数量为 531 人,与过去十年相比增长了 58.7%。正电子发射断层扫描/计算机断层扫描(PET/CT)、单光子发射计算机断层扫描(SPECT)和单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)是主要的核医学设施,调查科室总数分别为18、24和34个。与 2005 年相比,质量控制结果有了明显改善。闪烁扫描程序总数估计为 199 607 次(153 185 次 SPECT 和 46 422 次 PET/CT)。据估计,2018 年期间,SPECT 扫描图像的年数量为每千人 8.9 张,PET/CT 扫描图像的年数量为每千人 2.7 张。2018 年最常见的放射性碘靶向治疗是甲亢的 131I 靶向治疗。结论 核医学在过去 10 年中在北京经历了快速发展,无论是人员、设备还是闪烁成像。今后的工作重点将放在新同位素在诊断中的应用、实施质量策略和加强培训等方面。
{"title":"Status and Development of Nuclear Medicine Over One Decade in Beijing","authors":"Fei Luo, J. Geng, Sheng-zu Chen","doi":"10.1055/s-0044-1778712","DOIUrl":"https://doi.org/10.1055/s-0044-1778712","url":null,"abstract":"\u0000 Objective Our objective was to investigate the basic information of the personnel and facilities of nuclear medicine in Beijing.\u0000 Methods This survey was performed by the Beijing Quality Control Center in 2018. The investigation included personnel, equipment, and clinical applications, and data were then compared with previous surveys. The paper questionnaires were used for the survey, which required information about the personnel, devices, and clinical applications.\u0000 Results About 38 nuclear medicine departments in Beijing were involved in the survey. The number of nuclear medicine staff was 531 in 2018, showing an increase of 58.7% over the past decade. Positron emission tomography/computed tomography (PET/CT), single-photon emission computed tomography (SPECT), and single-photon emission computed tomography/computed tomography (SPECT/CT) represented the main nuclear medicine facilities, and the total number of surveyed departments was 18, 24, and 34, respectively. The quality control results showed significant improvement from the 2005 levels. The total number of scintigraphy procedures was estimated at 199,607 (153,185 SPECT and 46,422 PET/CT). The estimated annual number of scintigraphy images was 8.9 per 1,000 population for SPECT and 2.7 per 1,000 population for PET/CT during 2018. The most frequent radioiodine-targeted therapy was 131I-targeted therapy for hyperthyroidism in 2018.\u0000 Conclusions Nuclear medicine has experienced rapid growth in the past 10 years in Beijing, either in personnel, equipment, and scintigraphy. Future efforts will focus on the use of new isotopes in the diagnosis, implementing quality strategy, and enhancing training.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140714369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Response to PRRNT in a Rare Case of Metastatic Renal Neuroendocrine Carcinoma 一个罕见的转移性肾神经内分泌癌病例对 PRRNT 的治疗反应
IF 0.6 Pub Date : 2024-04-09 DOI: 10.1055/s-0044-1785461
S. Sunny, Julie Hephzibah, Raju Titus Chacko, T. Kodiatte
Neuroendocrine tumors (NETs) are a rare spectrum of neoplasms that are characterized by neuroendocrine and neural differentiation. The treatment can be challenging in view of the heterogeneity in differentiation and behavior. Primary renal origin NETs are rare and only a few cases have been reported in the literature. There is limited knowledge on their presentation and response to various lines of treatment. We report a case of a patient with a metastatic renal NET from a rare histological subtype of large cell neuroendocrine carcinoma, known to cause aggressive disease with poor prognosis. A multimodality treatment approach was followed. In spite of surgical management and second-line chemotherapy, the disease progressed. The patient subsequently received peptide receptor radionuclide therapy (PRRNT) using lutetium-177 DOTATATE, following which the patient demonstrated a remarkable clinical and radiological response and is stable to date. In a rare tumor with poor prognosis, the relevance of theranostics and the efficacy of targeted therapies like PRRNT are noteworthy.
神经内分泌肿瘤(NET)是一种罕见的肿瘤,以神经内分泌和神经分化为特征。鉴于分化和行为的异质性,治疗具有挑战性。原发性肾源性 NET 非常罕见,文献中仅有少数病例报道。人们对它们的表现和对各种治疗方法的反应了解有限。我们报告了一例罕见组织学亚型大细胞神经内分泌癌转移性肾NET患者的病例。患者接受了多模式治疗。尽管进行了手术治疗和二线化疗,但病情仍有进展。随后,患者接受了使用 177 DOTATATE 镥的肽受体放射性核素治疗(PRRNT),随后患者表现出了显著的临床和放射学反应,至今病情稳定。对于预后不良的罕见肿瘤,治疗学的相关性和 PRRNT 等靶向疗法的疗效值得关注。
{"title":"Therapeutic Response to PRRNT in a Rare Case of Metastatic Renal Neuroendocrine Carcinoma","authors":"S. Sunny, Julie Hephzibah, Raju Titus Chacko, T. Kodiatte","doi":"10.1055/s-0044-1785461","DOIUrl":"https://doi.org/10.1055/s-0044-1785461","url":null,"abstract":"Neuroendocrine tumors (NETs) are a rare spectrum of neoplasms that are characterized by neuroendocrine and neural differentiation. The treatment can be challenging in view of the heterogeneity in differentiation and behavior. Primary renal origin NETs are rare and only a few cases have been reported in the literature. There is limited knowledge on their presentation and response to various lines of treatment. We report a case of a patient with a metastatic renal NET from a rare histological subtype of large cell neuroendocrine carcinoma, known to cause aggressive disease with poor prognosis. A multimodality treatment approach was followed. In spite of surgical management and second-line chemotherapy, the disease progressed. The patient subsequently received peptide receptor radionuclide therapy (PRRNT) using lutetium-177 DOTATATE, following which the patient demonstrated a remarkable clinical and radiological response and is stable to date. In a rare tumor with poor prognosis, the relevance of theranostics and the efficacy of targeted therapies like PRRNT are noteworthy.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"77 7","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140726500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts of the 19th International Conference on Radionuclide Therapy (ICRT), World Association of Nuclear Medicine, Muscat, Oman, 8-12 February, 2024. 第 19 届国际放射性核素治疗会议(ICRT)摘要,世界核医学协会,阿曼马斯喀特,2024 年 2 月 8-12 日。
IF 0.6 Pub Date : 2024-04-08 eCollection Date: 2024-03-01 DOI: 10.1055/s-0044-1782143
{"title":"Abstracts of the 19th International Conference on Radionuclide Therapy (ICRT), World Association of Nuclear Medicine, Muscat, Oman, 8-12 February, 2024.","authors":"","doi":"10.1055/s-0044-1782143","DOIUrl":"https://doi.org/10.1055/s-0044-1782143","url":null,"abstract":"","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"23 1","pages":"57-70"},"PeriodicalIF":0.6,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual Metastatic Sites and Radioiodine Uptake in Patients of Differentiated Thyroid Carcinoma with Atypical Clinical Presentations: Utilization of 131I-Whole-Body Scintigraphy with Regional SPECT/CT 临床表现不典型的分化型甲状腺癌患者的异常转移部位和放射性碘摄取:131I全身闪烁扫描与区域SPECT/CT的应用
IF 0.6 Pub Date : 2024-04-01 DOI: 10.1055/s-0044-1779750
Yeshwanth Edamadaka, R. Parghane, Sandip Basu
Differentiated thyroid carcinoma (DTC) usually is slow growing and carries a good prognosis. It most commonly tends to spread locally to regional lymph nodes in 20 to 60% of patients. The presence of distant metastasis impacts overall survival and prognosis. The lungs, bones, and the brain are typically involved in distant sites with less common metastatic sites that include the liver, kidney, skeletal muscle, adrenal glands, bladder, and skin. These unusual sites are rare and pose a diagnostic challenge and impact clinical decision-making to a great extent. The radioiodine 131I whole-body scintigraphy with single-photon emission computed tomography/computed tomography can provide a thorough investigation of unusual sites of uptake leading to diagnosis of these metastases. We present a case series of DTC showing unusual sites of metastasis and/or radioiodine uptake in urinary bladder, in the third metacarpal bone of left hand and lastly in the forearm at postoperative hypertrophic scar area.
分化型甲状腺癌(DTC)通常生长缓慢,预后良好。最常见的情况是,20%到60%的患者会发生局部淋巴结转移。远处转移的出现会影响总体生存率和预后。肺、骨骼和大脑是典型的远处转移部位,较少见的转移部位包括肝脏、肾脏、骨骼肌、肾上腺、膀胱和皮肤。这些异常部位非常罕见,给诊断带来了挑战,并在很大程度上影响了临床决策。放射性碘 131I 全身闪烁扫描与单光子发射计算机断层扫描/计算机断层扫描可对异常部位的摄取进行彻底检查,从而确诊这些转移灶。我们介绍了一个 DTC 病例系列,该病例显示膀胱、左手第三掌骨和前臂术后肥厚瘢痕处存在异常部位的转移和/或放射性碘摄取。
{"title":"Unusual Metastatic Sites and Radioiodine Uptake in Patients of Differentiated Thyroid Carcinoma with Atypical Clinical Presentations: Utilization of 131I-Whole-Body Scintigraphy with Regional SPECT/CT","authors":"Yeshwanth Edamadaka, R. Parghane, Sandip Basu","doi":"10.1055/s-0044-1779750","DOIUrl":"https://doi.org/10.1055/s-0044-1779750","url":null,"abstract":"Differentiated thyroid carcinoma (DTC) usually is slow growing and carries a good prognosis. It most commonly tends to spread locally to regional lymph nodes in 20 to 60% of patients. The presence of distant metastasis impacts overall survival and prognosis. The lungs, bones, and the brain are typically involved in distant sites with less common metastatic sites that include the liver, kidney, skeletal muscle, adrenal glands, bladder, and skin. These unusual sites are rare and pose a diagnostic challenge and impact clinical decision-making to a great extent. The radioiodine 131I whole-body scintigraphy with single-photon emission computed tomography/computed tomography can provide a thorough investigation of unusual sites of uptake leading to diagnosis of these metastases. We present a case series of DTC showing unusual sites of metastasis and/or radioiodine uptake in urinary bladder, in the third metacarpal bone of left hand and lastly in the forearm at postoperative hypertrophic scar area.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"375 1","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140759870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Ga-68 PSMA PET/CT and Multiparametric MRI for Initial Detection and Staging of Prostate Cancer. 用于前列腺癌初步检测和分期的Ga-68 PSMA PET/CT与多参数磁共振成像的比较
IF 0.6 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-04-01 eCollection Date: 2024-06-01 DOI: 10.1055/s-0044-1779749
Dinesh Kumar Gauthaman, Karuna Luthra, Vikram Lele

Background  Multiparametric magnetic resonance imaging (mpMRI) is widely used for the evaluation of prostate cancer and is known to have better accuracy. Gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) is a radiotracer that shows high localization in prostate cancer cells. Purpose  The purpose of this study was to assess the sensitivity and utility of Ga-68 PSMA positron emission tomography/computed tomography (PET/CT) in comparison with mpMRI as a noninvasive imaging technique for the initial diagnosis and locoregional staging of prostate cancer using transrectal ultrasound (TRUS)-guided biopsy as gold standard. Materials and Methods  This prospective observational study conducted from August 2017 to April 2020 evaluated 60 men ( n  = 60) with biopsy-proven prostate carcinoma. They underwent mpMRI and Ga-68 PSMA PET/CT scans within 14 days with TRUS biopsy being gold standard. T staging of disease, N staging of lymph nodes within the pelvis, and M staging of lesions in pelvic bones (within the imaging field of mpMRI) were compared using PSPP version 1.0.1 statistical software. Results  All 60 men with a mean age of 69.9 ± 9.35 years showed Ga-68 PSMA avid disease, whereas 55 were detected by mpMRI. The sensitivity in detection of prostate lesions (with 95% confidence interval) was 99.08% for Ga-68 PSMA PET/CT and 84.40% for mpMRI. Ga-68 PSMA PET/CT detected greater number of patients with regional lymph nodal involvement (19/60) as compared with mpMRI (12/60). Ga-68 PSMA PET/CT showed PSMA avid pelvic skeletal lesions in nine patients, whereas mpMRI detected pelvic lesions in six patients. In addition, four other patients showed extrapelvic skeletal lesions on Ga-68 PSMA PET/CT. Conclusion  Ga-68 PSMA PET/CT has superior sensitivity in detection of primary prostate tumor, as compared with mpMRI. Both modalities correlate well in detection of seminal vesicle involvement. Ga-68 PSMA PET/CT outperformed mpMRI in detection of lymph nodal and skeletal metastases. Hence, Ga-68 PSMA PET/CT should be considered as first-line diagnostic modality for carcinoma prostate. Summary Statement : Ga-68 PSMA PET/CT shows superior diagnostic performance than mpMRI in the evaluation of prostate cancer.

背景 多参数磁共振成像(mpMRI)被广泛用于前列腺癌的评估,其准确性较高。镓-68前列腺特异性膜抗原(Ga-68 PSMA)是一种放射性示踪剂,可在前列腺癌细胞中高度定位。目的 本研究旨在评估 Ga-68 PSMA 正电子发射断层扫描/计算机断层扫描(PET/CT)与 mpMRI 作为无创成像技术的敏感性和实用性,以经直肠超声(TRUS)引导的活检为金标准,用于前列腺癌的初步诊断和局部分期。材料与方法 这项前瞻性观察研究于 2017 年 8 月至 2020 年 4 月进行,评估了 60 名经活检证实患有前列腺癌的男性(n = 60)。他们在14天内接受了mpMRI和Ga-68 PSMA PET/CT扫描,TRUS活检为金标准。使用 PSPP 1.0.1 版统计软件比较了疾病的 T 分期、盆腔内淋巴结的 N 分期和盆腔骨骼病变的 M 分期(在 mpMRI 的成像范围内)。结果 平均年龄(69.9 ± 9.35)为 69.9 ± 9.35 岁的 60 名男性均出现 Ga-68 PSMA 阳性病变,而 mpMRI 检测出 55 例。Ga-68 PSMA PET/CT 检测前列腺病变的灵敏度为 99.08%(置信区间为 95%),mpMRI 检测前列腺病变的灵敏度为 84.40%。与 mpMRI(12/60)相比,Ga-68 PSMA PET/CT 检测出更多区域淋巴结受累的患者(19/60)。Ga-68 PSMA PET/CT 在 9 名患者中发现了 PSMA 阳性骨盆骨骼病变,而 mpMRI 在 6 名患者中发现了骨盆病变。此外,另有四名患者的Ga-68 PSMA PET/CT显示盆腔外骨骼病变。结论 与 mpMRI 相比,Ga-68 PSMA PET/CT 在检测原发性前列腺肿瘤方面具有更高的灵敏度。两种模式在检测精囊受累方面都有很好的相关性。在检测淋巴结和骨骼转移方面,Ga-68 PSMA PET/CT 优于 mpMRI。因此,Ga-68 PSMA PET/CT应被视为前列腺癌的一线诊断方法。总结陈述 :在评估前列腺癌方面,Ga-68 PSMA PET/CT 的诊断性能优于 mpMRI。
{"title":"Comparison of Ga-68 PSMA PET/CT and Multiparametric MRI for Initial Detection and Staging of Prostate Cancer.","authors":"Dinesh Kumar Gauthaman, Karuna Luthra, Vikram Lele","doi":"10.1055/s-0044-1779749","DOIUrl":"10.1055/s-0044-1779749","url":null,"abstract":"<p><p><b>Background</b>  Multiparametric magnetic resonance imaging (mpMRI) is widely used for the evaluation of prostate cancer and is known to have better accuracy. Gallium-68 prostate-specific membrane antigen (Ga-68 PSMA) is a radiotracer that shows high localization in prostate cancer cells. <b>Purpose</b>  The purpose of this study was to assess the sensitivity and utility of Ga-68 PSMA positron emission tomography/computed tomography (PET/CT) in comparison with mpMRI as a noninvasive imaging technique for the initial diagnosis and locoregional staging of prostate cancer using transrectal ultrasound (TRUS)-guided biopsy as gold standard. <b>Materials and Methods</b>  This prospective observational study conducted from August 2017 to April 2020 evaluated 60 men ( <i>n</i>  = 60) with biopsy-proven prostate carcinoma. They underwent mpMRI and Ga-68 PSMA PET/CT scans within 14 days with TRUS biopsy being gold standard. T staging of disease, N staging of lymph nodes within the pelvis, and M staging of lesions in pelvic bones (within the imaging field of mpMRI) were compared using PSPP version 1.0.1 statistical software. <b>Results</b>  All 60 men with a mean age of 69.9 ± 9.35 years showed Ga-68 PSMA avid disease, whereas 55 were detected by mpMRI. The sensitivity in detection of prostate lesions (with 95% confidence interval) was 99.08% for Ga-68 PSMA PET/CT and 84.40% for mpMRI. Ga-68 PSMA PET/CT detected greater number of patients with regional lymph nodal involvement (19/60) as compared with mpMRI (12/60). Ga-68 PSMA PET/CT showed PSMA avid pelvic skeletal lesions in nine patients, whereas mpMRI detected pelvic lesions in six patients. In addition, four other patients showed extrapelvic skeletal lesions on Ga-68 PSMA PET/CT. <b>Conclusion</b>  Ga-68 PSMA PET/CT has superior sensitivity in detection of primary prostate tumor, as compared with mpMRI. Both modalities correlate well in detection of seminal vesicle involvement. Ga-68 PSMA PET/CT outperformed mpMRI in detection of lymph nodal and skeletal metastases. Hence, Ga-68 PSMA PET/CT should be considered as first-line diagnostic modality for carcinoma prostate. <b>Summary Statement</b> : Ga-68 PSMA PET/CT shows superior diagnostic performance than mpMRI in the evaluation of prostate cancer.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"23 2","pages":"79-87"},"PeriodicalIF":0.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone Metastasis from Renal Cancer Coinciding with the Same Anatomical Position as a Vertebral Hemangioma: A Collision Lesion Case Report. 肾癌骨转移与椎体血管瘤的解剖位置相同:碰撞病变病例报告。
IF 0.6 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-03-28 eCollection Date: 2024-06-01 DOI: 10.1055/s-0044-1779747
André Marcondes Braga Ribeiro, Amanda Silles Borin, Guilherme Dias Rocha de Mello, Rubens Chojniak

Collisions lesions are rare neoplasms where two histologically distinct tumors coexist in the same organ or anatomical site. Vertebral hemangiomas (VHs) are the most common lesions involving the vertebral bodies and imaging findings of typical and atypical hemangiomas, variant forms of hemangioma such as aggressive hemangiomas are well known, but collision lesions involving VHs are extremely rare. This article presents a case report of a 73-year-old male patient diagnosed with clear cell renal cancer in a rare presentation of a bone metastasis coinciding with the same anatomical position as a VH (collision lesion). This required a multidisciplinary approach involving various diagnostic techniques to determine the best therapeutic management.

碰撞病变是一种罕见的肿瘤,即在同一器官或解剖部位同时存在两种组织学上不同的肿瘤。椎体血管瘤(VHs)是最常见的累及椎体的病变,典型和非典型血管瘤、侵袭性血管瘤等变异型血管瘤的影像学发现已广为人知,但累及椎体血管瘤的碰撞病变却极为罕见。本文报告了一例 73 岁男性患者的病例,该患者被诊断为透明细胞肾癌,其骨转移瘤的解剖位置与 VH 相同(碰撞病变),这种情况十分罕见。这就需要采用涉及各种诊断技术的多学科方法来确定最佳治疗方案。
{"title":"Bone Metastasis from Renal Cancer Coinciding with the Same Anatomical Position as a Vertebral Hemangioma: A Collision Lesion Case Report.","authors":"André Marcondes Braga Ribeiro, Amanda Silles Borin, Guilherme Dias Rocha de Mello, Rubens Chojniak","doi":"10.1055/s-0044-1779747","DOIUrl":"10.1055/s-0044-1779747","url":null,"abstract":"<p><p>Collisions lesions are rare neoplasms where two histologically distinct tumors coexist in the same organ or anatomical site. Vertebral hemangiomas (VHs) are the most common lesions involving the vertebral bodies and imaging findings of typical and atypical hemangiomas, variant forms of hemangioma such as aggressive hemangiomas are well known, but collision lesions involving VHs are extremely rare. This article presents a case report of a 73-year-old male patient diagnosed with clear cell renal cancer in a rare presentation of a bone metastasis coinciding with the same anatomical position as a VH (collision lesion). This required a multidisciplinary approach involving various diagnostic techniques to determine the best therapeutic management.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"23 2","pages":"135-140"},"PeriodicalIF":0.6,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of 18 F-FDG-PET/CT in an AML-M5a Subtype Patient with Rare Constellation of Hemophagocytic Lymphohistiocytosis & Bilateral Multiple Breast Chloromas. 18 F-FDG-PET/CT在患有嗜血细胞淋巴组织细胞增多症和双侧多发性乳房绿巨人的AML-M5a亚型患者中的作用
IF 0.6 Pub Date : 2024-02-13 eCollection Date: 2024-03-01 DOI: 10.1055/s-0044-1779280
Yuvan Shrinivas, Shanmuga Sundaram Palaniswamy, Padma Subramanyam

We report a treated case of acute myeloid leukemia (AML-M5a subtype) with monocytic differentiation (AMoL) presenting with fever and body pains. Initial 18 F-FDG-PET/CT ( 18 F-flurodeoxyglucose positron emission tomography/computed tomography) identified multiple lymph nodal, and marrow lesions. Biopsy confirmed hemophagocytic lymphohistiocytosis (HLH). Post HLH treatment, follow-up PET/CT demonstrated unsuspected FDG avid bilateral breast lesions ( n  = 5), which proved to be chloromas, that is, extranodal manifestation of AML. 18 F-FDG-PET/CT has helped not only in identifying the various sites of disease involvement but also in guiding the sites for biopsy. Finally, 18 F-FDG-PET/CT was useful in monitoring therapy response for both these coexisting pathologies, which are said to be resistant to treatment based on FLT3-ITD tyrosine kinase-3 internal tandem duplication mutation positivity and high-grade AML status. This case represents a rare constellation of different etiologies that needed to be differentiated. It also emphasizes the challenges in interpreting PET/CT findings, especially in difficult clinical scenarios. Disease distribution in HLH/presence of chloromas, etc., can mimic stage IV lymphoma in a known case of AML. So the nuclear medicine physician should be aware of the different complications in the background of AML, especially in patients with poor prognostic factors.

我们报告了一例急性髓性白血病(AML-M5a 亚型)伴单核细胞分化(AMoL)的治疗病例,患者表现为发热和全身疼痛。最初的18 F-FDG-PET/CT(18 F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描)发现了多个淋巴结和骨髓病变。活检证实了嗜血细胞淋巴组织细胞增多症(HLH)。HLH治疗后,随访的PET/CT显示了未被发现的FDG阳性双侧乳腺病变(n = 5),这被证明是叶绿瘤,即急性髓细胞性淋巴瘤的结外表现。18 F-FDG-PET/CT不仅有助于确定疾病受累的不同部位,还有助于指导活检部位。最后,18 F-FDG-PET/CT有助于监测这两种并存病变的治疗反应,根据FLT3-ITD酪氨酸激酶-3内部串联重复突变阳性和高级别急性髓细胞性白血病状态,这两种病变被认为是耐药的。该病例代表了一种罕见的不同病因组合,需要加以区分。它还强调了解读 PET/CT 发现的挑战,尤其是在困难的临床情况下。HLH中的疾病分布/绿瘤的存在等,可能会在已知的急性髓细胞性淋巴瘤病例中模拟出IV期淋巴瘤。因此,核医学医生应了解急性髓细胞性白血病背景下的各种并发症,尤其是预后不良的患者。
{"title":"Role of <sup>18</sup> F-FDG-PET/CT in an AML-M5a Subtype Patient with Rare Constellation of Hemophagocytic Lymphohistiocytosis & Bilateral Multiple Breast Chloromas.","authors":"Yuvan Shrinivas, Shanmuga Sundaram Palaniswamy, Padma Subramanyam","doi":"10.1055/s-0044-1779280","DOIUrl":"https://doi.org/10.1055/s-0044-1779280","url":null,"abstract":"<p><p>We report a treated case of acute myeloid leukemia (AML-M5a subtype) with monocytic differentiation (AMoL) presenting with fever and body pains. Initial <sup>18</sup> F-FDG-PET/CT ( <sup>18</sup> F-flurodeoxyglucose positron emission tomography/computed tomography) identified multiple lymph nodal, and marrow lesions. Biopsy confirmed hemophagocytic lymphohistiocytosis (HLH). Post HLH treatment, follow-up PET/CT demonstrated unsuspected FDG avid bilateral breast lesions ( <i>n</i>  = 5), which proved to be chloromas, that is, extranodal manifestation of AML. <sup>18</sup> F-FDG-PET/CT has helped not only in identifying the various sites of disease involvement but also in guiding the sites for biopsy. Finally, <sup>18</sup> F-FDG-PET/CT was useful in monitoring therapy response for both these coexisting pathologies, which are said to be resistant to treatment based on FLT3-ITD tyrosine kinase-3 internal tandem duplication mutation positivity and high-grade AML status. This case represents a rare constellation of different etiologies that needed to be differentiated. It also emphasizes the challenges in interpreting PET/CT findings, especially in difficult clinical scenarios. Disease distribution in HLH/presence of chloromas, etc., can mimic stage IV lymphoma in a known case of AML. So the nuclear medicine physician should be aware of the different complications in the background of AML, especially in patients with poor prognostic factors.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"23 1","pages":"49-53"},"PeriodicalIF":0.6,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive Value of Corrected 18 F-FDG PET/CT Baseline Parameters for Primary DLBCL Prognosis: A Single-center Study. 校正 18 F-FDG PET/CT 基线参数对原发性 DLBCL 预后的预测价值:一项单中心研究。
IF 0.6 Pub Date : 2024-02-13 eCollection Date: 2024-03-01 DOI: 10.1055/s-0044-1779282
Min Li, Jianpeng Liu, Fangfei Liu, Rongbin Lv, Haowei Bai, Shuyong Liu

Objective  The purpose of this study was to evaluate the prognostic significance of corrected baseline metabolic parameters in fluorodeoxyglucose positron emission tomography imaging ( 18 F-FDG PET/CT) for 3-year progression-free survival (PFS) in patients with primary diffuse large B cell lymphoma (DLBCL). Patients and Methods  Retrospective clinical and pathological data were collected for 199 patients of DLBCL diagnosed between January 2018 and January 2021. All patients underwent 18 F-FDG PET/CT scans without any form of treatment. The corrected maximum standardized uptake value (corSUVmax), corrected mean standardized uptake value (corSUVmean), corrected whole-body tumor metabolic volume sum (corMTVsum), and corrected total lesion glycolysis of whole body (corTLGtotal) were corrected using the SUVmean in a 1-cm diameter mediastinal blood pool (MBP) from the descending thoracic aorta of patients. Kaplan-Meier survival curves and Cox regression were used to examine the predictive significance of corrected baseline metabolic parameters on 3-year PFS of patients. The incremental values of corrected baseline metabolic parameters were evaluated by using Harrell's C-indices, receiver operating characteristic, and Decision Curve Analysis. Results  The multivariate analysis revealed that only the National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and corMTVsum had an effect on 3-year PFS of patients ( p  < 0.05, respectively). The Kaplan-Meier survival analysis demonstrated significant differences in PFS between the risk groups classified by corSUVsum, corMTVsum, and corTLGtotal (log-rank test, p  < 0.05). The predictive model composed of corMTVsum and corTLGtotal surpasses the predictive performance of the model incorporating MTVsum and TLGtotal. The optimal performance was observed when corMTVsum was combined with NCCN-IPI, resulting in a Harrell's C index of 0.785 and area under the curve values of 0.863, 0.891, and 0.947 for the 1-, 2-, and 3-year PFS rates, respectively. Conclusion  The corMTVsum offers significant prognostic value for patients with DLBCL. Furthermore, the combination of corMTVsum with the NCCN-IPI can provide an accurate prediction of the prognosis.

目的 本研究旨在评估氟脱氧葡萄糖正电子发射断层成像(18 F-FDG PET/CT)中校正基线代谢参数对原发性弥漫大 B 细胞淋巴瘤(DLBCL)患者 3 年无进展生存期(PFS)的预后意义。患者和方法 收集了2018年1月至2021年1月期间确诊的199例DLBCL患者的回顾性临床和病理数据。所有患者均在未接受任何治疗的情况下接受了 18 F-FDG PET/CT 扫描。校正后的最大标准化摄取值(corSUVmax)、校正后的平均标准化摄取值(corSUVmean)、校正后的全身肿瘤代谢体积总和(corMTVsum)和校正后的全身病变糖酵解总量(corTLGtotal)均使用患者胸主动脉降支直径为1厘米的纵隔血池(MBP)中的SUVmean进行校正。采用卡普兰-梅耶生存曲线和 Cox 回归检验校正基线代谢参数对患者 3 年 PFS 的预测意义。使用哈雷尔 C 指数、接受者操作特征和决策曲线分析评估了校正基线代谢参数的增量值。结果 多变量分析显示,只有美国国立综合癌症网络(NCCN)-国际预后指数(IPI)和 corMTVsum 对患者的 3 年 PFS 有影响(p p 结论 corMTVsum 对 DLBCL 患者具有显著的预后价值。此外,将 corMTVsum 与 NCCN-IPI 结合使用可准确预测预后。
{"title":"Predictive Value of Corrected <sup>18</sup> F-FDG PET/CT Baseline Parameters for Primary DLBCL Prognosis: A Single-center Study.","authors":"Min Li, Jianpeng Liu, Fangfei Liu, Rongbin Lv, Haowei Bai, Shuyong Liu","doi":"10.1055/s-0044-1779282","DOIUrl":"https://doi.org/10.1055/s-0044-1779282","url":null,"abstract":"<p><p><b>Objective</b>  The purpose of this study was to evaluate the prognostic significance of corrected baseline metabolic parameters in fluorodeoxyglucose positron emission tomography imaging ( <sup>18</sup> F-FDG PET/CT) for 3-year progression-free survival (PFS) in patients with primary diffuse large B cell lymphoma (DLBCL). <b>Patients and Methods</b>  Retrospective clinical and pathological data were collected for 199 patients of DLBCL diagnosed between January 2018 and January 2021. All patients underwent <sup>18</sup> F-FDG PET/CT scans without any form of treatment. The corrected maximum standardized uptake value (corSUVmax), corrected mean standardized uptake value (corSUVmean), corrected whole-body tumor metabolic volume sum (corMTVsum), and corrected total lesion glycolysis of whole body (corTLGtotal) were corrected using the SUVmean in a 1-cm diameter mediastinal blood pool (MBP) from the descending thoracic aorta of patients. Kaplan-Meier survival curves and Cox regression were used to examine the predictive significance of corrected baseline metabolic parameters on 3-year PFS of patients. The incremental values of corrected baseline metabolic parameters were evaluated by using Harrell's C-indices, receiver operating characteristic, and Decision Curve Analysis. <b>Results</b>  The multivariate analysis revealed that only the National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and corMTVsum had an effect on 3-year PFS of patients ( <i>p</i>  < 0.05, respectively). The Kaplan-Meier survival analysis demonstrated significant differences in PFS between the risk groups classified by corSUVsum, corMTVsum, and corTLGtotal (log-rank test, <i>p</i>  < 0.05). The predictive model composed of corMTVsum and corTLGtotal surpasses the predictive performance of the model incorporating MTVsum and TLGtotal. The optimal performance was observed when corMTVsum was combined with NCCN-IPI, resulting in a Harrell's C index of 0.785 and area under the curve values of 0.863, 0.891, and 0.947 for the 1-, 2-, and 3-year PFS rates, respectively. <b>Conclusion</b>  The corMTVsum offers significant prognostic value for patients with DLBCL. Furthermore, the combination of corMTVsum with the NCCN-IPI can provide an accurate prediction of the prognosis.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"23 1","pages":"33-42"},"PeriodicalIF":0.6,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardizing Normal Reference Value for Thyroid Uptake of Technetium-99m Pertechnetate in Nepalese Population. 尼泊尔人群甲状腺摄取锝-99m Pertechnetate 正常参考值的标准化。
IF 0.6 Pub Date : 2024-02-13 eCollection Date: 2024-03-01 DOI: 10.1055/s-0044-1779283
Jiwan Paudel, Babita Bhattarai

Objective  Changes in normal reference values of thyroid uptake for iodine have been reported due to geographical and chronological fluctuations in dietary iodine intake in different populations. Nepal is a country with mixed ethnicity, with access to dietary iodine in the form of successful universal salt iodination program by the government of Nepal since 1973. The aim of this study was to establish the normal reference values for thyroid uptake of technetium-99m (Tc-99m) pertechnetate in the Nepalese population in iodine sufficiency era. Methods  We prospectively evaluated 52 clinically and biochemically euthyroid participants (46 females and 6 males) with age range from 20 to 71 years who underwent a thyroid Tc-99m pertechnetate scan and uptake between December 2019 to November 2023 in the Department of Nuclear Medicine, Chitwan Medical College fulfilling inclusion/exclusion criteria. Biochemical thyroid function tests were reviewed and Tc-99m pertechnetate thyroid uptake values were determined for each patient. Blood was withdrawn for thyroid hormone assessment. Euthyroid participants were then administered 3.5 to 4.5 mCi of Tc-99m pertechnetate intravenously and their percentage thyroid uptake was calculated after 20 minutes. Results  The mean and median uptake of Tc-99m pertechnetate in euthyroid patients were 1.26 and 0.85%, respectively, and the interquartile range was 0.7 to 1.7%. The normal reference uptake value for Tc-99m pertechnetate in the studied population ranged between 0.3 and 3.6%. The fifth and 95th percentiles for pertechnetate uptake were 0.5 and 2.9%, respectively. Conclusion  The normal reference range for Tc-99m pertechnetate thyroid uptake in Nepalese population was 0.5 to 2.9% that is lower than the currently accepted international standard of 0.75 to 4.5%. Uptake also increased with increasing age. This study highlights the importance of periodically redefining the geographic location specific normal thyroid uptake reference values.

目标 据报道,由于不同人群膳食碘摄入量的地域性和时间性波动,甲状腺摄碘量的正常参考值也会发生变化。尼泊尔是一个多民族国家,自 1973 年以来,尼泊尔政府成功实施了全民食盐加碘计划,使人们能够从膳食中摄取碘。本研究旨在确定碘充足时代尼泊尔人群甲状腺摄取全硫酸锝-99m(Tc-99m)的正常参考值。方法 我们对符合纳入/排除标准的 52 名临床和生化甲状腺功能正常的参与者(46 名女性和 6 名男性)进行了前瞻性评估,这些参与者在 2019 年 12 月至 2023 年 11 月期间在奇特旺医学院核医学系接受了甲状腺全硫酸锝(Tc-99m pertechnetate)扫描和摄取。对每位患者的甲状腺生化功能检查进行复查,并确定甲状腺Tc-99m过硫酸盐摄取值。抽血进行甲状腺激素评估。然后给甲状腺功能正常的参与者静脉注射 3.5 至 4.5 mCi 的全硫酸锝,20 分钟后计算他们的甲状腺摄取百分比。结果 甲状腺功能正常患者的 Tc-99m 全硫酸盐摄取率的平均值和中位数分别为 1.26% 和 0.85%,四分位数间范围为 0.7% 至 1.7%。研究人群的锝-99m过硫酸盐正常参考摄取值介于0.3%和3.6%之间。过硫酸盐摄取量的第五百分位数和第九十五百分位数分别为 0.5% 和 2.9%。结论 尼泊尔人群甲状腺摄取Tc-99m过硫酸盐的正常参考范围为0.5%至2.9%,低于目前公认的0.75%至4.5%的国际标准。摄取率也随着年龄的增长而增加。这项研究强调了定期重新定义特定地理位置正常甲状腺摄取参考值的重要性。
{"title":"Standardizing Normal Reference Value for Thyroid Uptake of Technetium-99m Pertechnetate in Nepalese Population.","authors":"Jiwan Paudel, Babita Bhattarai","doi":"10.1055/s-0044-1779283","DOIUrl":"https://doi.org/10.1055/s-0044-1779283","url":null,"abstract":"<p><p><b>Objective</b>  Changes in normal reference values of thyroid uptake for iodine have been reported due to geographical and chronological fluctuations in dietary iodine intake in different populations. Nepal is a country with mixed ethnicity, with access to dietary iodine in the form of successful universal salt iodination program by the government of Nepal since 1973. The aim of this study was to establish the normal reference values for thyroid uptake of technetium-99m (Tc-99m) pertechnetate in the Nepalese population in iodine sufficiency era. <b>Methods</b>  We prospectively evaluated 52 clinically and biochemically euthyroid participants (46 females and 6 males) with age range from 20 to 71 years who underwent a thyroid Tc-99m pertechnetate scan and uptake between December 2019 to November 2023 in the Department of Nuclear Medicine, Chitwan Medical College fulfilling inclusion/exclusion criteria. Biochemical thyroid function tests were reviewed and Tc-99m pertechnetate thyroid uptake values were determined for each patient. Blood was withdrawn for thyroid hormone assessment. Euthyroid participants were then administered 3.5 to 4.5 mCi of Tc-99m pertechnetate intravenously and their percentage thyroid uptake was calculated after 20 minutes. <b>Results</b>  The mean and median uptake of Tc-99m pertechnetate in euthyroid patients were 1.26 and 0.85%, respectively, and the interquartile range was 0.7 to 1.7%. The normal reference uptake value for Tc-99m pertechnetate in the studied population ranged between 0.3 and 3.6%. The fifth and 95th percentiles for pertechnetate uptake were 0.5 and 2.9%, respectively. <b>Conclusion</b>  The normal reference range for Tc-99m pertechnetate thyroid uptake in Nepalese population was 0.5 to 2.9% that is lower than the currently accepted international standard of 0.75 to 4.5%. Uptake also increased with increasing age. This study highlights the importance of periodically redefining the geographic location specific normal thyroid uptake reference values.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"23 1","pages":"25-32"},"PeriodicalIF":0.6,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concomitant Bilateral Inferior Gluteal Lymph Node Involvement in Metastatic Prostate Adenocarcinoma Detected on 68 Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography. 68 镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描检测到的转移性前列腺腺癌伴有双侧臀下淋巴结受累。
IF 0.6 Pub Date : 2024-02-06 eCollection Date: 2024-03-01 DOI: 10.1055/s-0044-1779281
Parth Baberwal, Sunita Sonavane, Sandip Basu

An unusual and unique case of prostate adenocarcinoma with involvement of bilateral inferior gluteal lymph nodes is reported. The patient was a 42-year-old male, with conventional prostatic adenocarcinoma (Gleason score: 5 + 4 = 9), who, during disease progression with rising serum prostate specific antigen levels following medical androgen deprivation therapy, demonstrated new prostate-specific membrane antigen expressing metastatic intermuscular deposits in the bilateral gluteal region, subsequently proven to be bilateral inferior gluteal nodal metastasis. A therapeutic implication to this may be that these nodes usually fall beyond the range covered by the therapeutic radiation field coverage where external radiotherapy is the advocated modality of choice and are not easily reachable through standard surgical procedures. As a result, they could have an impact on the way patients are clinically treated and on their prognosis.

报告了一例不寻常且独特的双侧臀下淋巴结受累的前列腺腺癌病例。患者是一名 42 岁的男性,患有传统的前列腺腺癌(格里森评分:5 + 4 = 9),在接受药物雄激素剥夺治疗后,随着病情的发展,血清前列腺特异性抗原水平不断升高,在双侧臀部区域出现了新的前列腺特异性膜抗原表达的转移性肌间沉积物,随后被证实为双侧臀下淋巴结转移。其治疗意义可能在于,这些结节通常位于治疗放射野覆盖范围之外,而外放射治疗是首选的治疗方式,并且不易通过标准外科手术到达。因此,它们可能会对患者的临床治疗方式和预后产生影响。
{"title":"Concomitant Bilateral Inferior Gluteal Lymph Node Involvement in Metastatic Prostate Adenocarcinoma Detected on <sup>68</sup> Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography.","authors":"Parth Baberwal, Sunita Sonavane, Sandip Basu","doi":"10.1055/s-0044-1779281","DOIUrl":"https://doi.org/10.1055/s-0044-1779281","url":null,"abstract":"<p><p>An unusual and unique case of prostate adenocarcinoma with involvement of bilateral inferior gluteal lymph nodes is reported. The patient was a 42-year-old male, with conventional prostatic adenocarcinoma (Gleason score: 5 + 4 = 9), who, during disease progression with rising serum prostate specific antigen levels following medical androgen deprivation therapy, demonstrated new prostate-specific membrane antigen expressing metastatic intermuscular deposits in the bilateral gluteal region, subsequently proven to be bilateral inferior gluteal nodal metastasis. A therapeutic implication to this may be that these nodes usually fall beyond the range covered by the therapeutic radiation field coverage where external radiotherapy is the advocated modality of choice and are not easily reachable through standard surgical procedures. As a result, they could have an impact on the way patients are clinically treated and on their prognosis.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"23 1","pages":"46-48"},"PeriodicalIF":0.6,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Nuclear Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1